Z, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the “Company”) (OTC:CYDY) announced today that on June 17, 2011 it filed for a provisional patent in the United States for the treatment of FIV, a retroviral infection in cats. The Company intends to develop this product as part of its wholly owned subsidiary CytoDyn Veterinary Medicine, LLC which the Company hopes will allow it to expand its science into a different market segment. The Company’s primary target will be a monoclonal antibody for the treatment of FIV infection in cats. According to Kenneth J. Van Ness, the Company’s President and Chief Executive Officer, “We believe our technology may allow us to target cell derived molecules that the Company thinks may be essential for retroviral infections.”
